Comparing cytotoxic backbones for first ‐line trastuzumab‐containing regimens in human epidermal growth factor receptor 2‐positive advanced oesophagogastric cancer: A meta‐analysis

In conclusion, trastuzumab plus doublet cytotoxic backbone containing oxaliplatin is preferable over the ToGA regimen with cisplatin. S‐1 can substitute capecitabine or 5‐FU when specific toxicities are encountered.

Source: International Journal of Cancer - March 14, 2018 Category: Cancer & Oncology Authors: Emil ter Veer, Aafke Creemers, Laura de Waal, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven Tags: Cancer Therapy and Prevention Source Type: research